PE20061246A1 - Metodo de tratamiento y prevencion - Google Patents
Metodo de tratamiento y prevencionInfo
- Publication number
- PE20061246A1 PE20061246A1 PE2005001384A PE2005001384A PE20061246A1 PE 20061246 A1 PE20061246 A1 PE 20061246A1 PE 2005001384 A PE2005001384 A PE 2005001384A PE 2005001384 A PE2005001384 A PE 2005001384A PE 20061246 A1 PE20061246 A1 PE 20061246A1
- Authority
- PE
- Peru
- Prior art keywords
- odiparcil
- administered
- refers
- heparin
- treatment
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title 1
- JRHNIQQUVJOPQC-AQNFWKISSA-N 4-methyl-7-[(2r,3r,4s,5s)-3,4,5-trihydroxythian-2-yl]oxychromen-2-one Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1SC[C@@H](O)[C@H](O)[C@H]1O JRHNIQQUVJOPQC-AQNFWKISSA-N 0.000 abstract 3
- 229950005036 odiparcil Drugs 0.000 abstract 3
- 102000004032 Heparin Cofactor II Human genes 0.000 abstract 2
- 108090000481 Heparin Cofactor II Proteins 0.000 abstract 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- 229960001138 acetylsalicylic acid Drugs 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009424 thromboembolic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UN METODO PARA TRATAR O PREVENIR TRANSTORNOS TROMBOEMBOLICOS QUE COMPRENDE LA ADMINISTRACION DE 4-METIL-2-OXO-2H-1-BENZOPIRAN-7-IL-5-TIO-ß-D-XILOPIRANOSIDO (ODIPARCIL) CUYO MECANISMO DE ACCION IMPLICA UNA BIOSINTESIS INCREMENTADA DE LOS GLUCOSAMINOGLUCANOS (GAG)Y LA POSTERIOR ELEVACION DE LA ACTIVIDAD ANTI-IIa VIA EL COFACTOR II DE LA HEPARINA (HCII). SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE ODIPARCIL QUE SE ADMINISTRA EN UNA CANTIDAD DE 125mg A 1g POR DIA DE PREFERENCIA 250 mg A 1g, 500 mg A 1g ENTRE OTROS, ADMINISTRADO DE PREFERENCIA CADA 12 HORAS. EL TRATAMIENTO COMPRENDE ADMINISTRAR UN CANTIDAD EFICAZ DE ODIPARCIL Y ASPIRINA O UNA HEPARINA LOS CUALES SE ADMINISTRAN INDEPENDIENTEMENTE
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63215304P | 2004-12-01 | 2004-12-01 | |
| US69172805P | 2005-06-17 | 2005-06-17 | |
| US72169105P | 2005-09-29 | 2005-09-29 | |
| US72471005P | 2005-10-07 | 2005-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20061246A1 true PE20061246A1 (es) | 2006-11-08 |
Family
ID=36565378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005001384A PE20061246A1 (es) | 2004-12-01 | 2005-11-29 | Metodo de tratamiento y prevencion |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR053789A1 (es) |
| PE (1) | PE20061246A1 (es) |
| TW (1) | TW200635580A (es) |
| UY (1) | UY29237A1 (es) |
| WO (1) | WO2006060647A1 (es) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2801055B1 (fr) * | 1999-11-17 | 2002-02-08 | Fournier Ind & Sante | Derives de beta-d-5-thioxylose, procede de preparation et utilisation en therapeutique |
-
2005
- 2005-11-29 TW TW094141796A patent/TW200635580A/zh unknown
- 2005-11-29 PE PE2005001384A patent/PE20061246A1/es not_active Application Discontinuation
- 2005-11-29 UY UY29237A patent/UY29237A1/es unknown
- 2005-11-29 AR ARP050104989A patent/AR053789A1/es not_active Application Discontinuation
- 2005-12-01 WO PCT/US2005/043602 patent/WO2006060647A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| UY29237A1 (es) | 2006-05-31 |
| TW200635580A (en) | 2006-10-16 |
| AR053789A1 (es) | 2007-05-23 |
| WO2006060647A1 (en) | 2006-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022010349A2 (pt) | Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma | |
| AR043188A1 (es) | Metodos y composiciones para el tratamiento de enfermedades y trastornos asociados con niveles elevados de citoquinas proinflamatorias | |
| AR026610A1 (es) | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| GT200300075BA (es) | Compuestos que modulan la actividad ppar y procedimientos para su preparacion (patente fraccionaria no. 2 de la solicitud no. pi-20030075) | |
| AR068185A1 (es) | Composiciones de tabletas de desintegracion oral de lamotrigina | |
| CY1118017T1 (el) | Υποβαλλοντας σε αγωγη την ανεπαρκεια και το ελλειμμα βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3 | |
| AR109170A2 (es) | Esfingomielinasa ácida para uso en la prevención o el tratamiento de la enfermedad de niemann-pick a o b en un paciente | |
| AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
| CY1116747T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
| AR062760A1 (es) | Administracion de inhibidores de dipeptidilpetidasa | |
| CY1110495T1 (el) | Χρηση ενος αγωνιστη υποδοχεα nmda για τη θεραπεια εμβοης που προκαλειται απο κοχλιακη διεγερτοτοξικοτητα | |
| CO6150188A2 (es) | Uso de teencteplasa para tratar un ictus isquemico agudo | |
| CO6280475A2 (es) | Metodo para tratar la deficiencia de vitamina b12 | |
| BR112023021131A2 (pt) | Tratamento de tremor essencial | |
| EE200200565A (et) | Vaskulaarse kahjustava toimega kombinatsioonravi | |
| UY32109A (es) | Métodos para utilizar composiciones de liberación sostenida de aminopiridina | |
| AR110800A1 (es) | MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA | |
| RU2015119377A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона | |
| PE20130147A1 (es) | Combinacion farmaceutica de teobromina y un agente antitusivo no opioide | |
| BRPI0509710A8 (pt) | Formulação de liberação controlada para administração oral de inibidor de hmg-coa redutase e método para preparação da mesma | |
| AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| WO2023069514A9 (en) | Bifunctional compounds for degrading itk via ubiquitin proteosome pathway | |
| PE20061246A1 (es) | Metodo de tratamiento y prevencion | |
| BR0108261A (pt) | Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |